|
1. Biologie
|
|
|
|
1.4 Biologie - Technos
|
|
|
|
|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12 Immunothérapies
|
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
5.6 ESMO
|
|
|
ESMO Immuno-Oncology Congress: Where the Community of Stakeholders Meets [ESMO]
|
|
|
|
|
|
This
Congress, to be held from 13-16 December in Geneva, Switzerland, is
designed for basic, translational and clinical researchers,
immunologists, oncology clinicians and other stakeholders, and will
attractone thousand participants who will benefit from a broad and
varied programme as well as focused sessions dedicated to different
tumour types and key aspects of this treatment modality.
|
|
|
|
|
|
|
5.7.1 SABCS-communiqués
|
|
|
|
5.8.2 ASH - Pharma
|
|
|
|
|
6.1 Observation
|
|
|
|
6.10 Politiques
|
|
|
|
6.7.3 DMP
|
|
|
|
6.9 Controverses
|
|
|